The GenTAC Alliance is a community of stakeholders committed to advancing our understanding of genetic thoracic aortic diseases and their treatment.
The Alliance builds upon the successes of the GenTAC Registry, which enrolled and followed participants from 2006 to 2016 and seeks to involve a much wider group of stakeholders and be more expansive in scope.
The goals of the GenTAC Alliance are to advance basic, translational and clinical research; educate and support patients, families, and clinicians; and coordinate, facilitate, and encourage the use of biospecimens and data across registries.
The Alliance welcomes patients, families, clinicians, researchers, and advocacy organizations to join our community of stakeholders in promoting and enhancing collaboration in education, research, and care with regard to genetically-triggered thoracic aortic disease and related cardiac and non-cardiac complications.Learn More
On Wednesday, May 13, 2020 at 2:00 PM, join experts from the GenTAC Basic and Translational Science Working Group for a webinar on methods and results for single cell sequencing of aortic tissues.Announcements
There have been theoretical concerns related to the use of ACE-inhibitors and ARBS in the setting of COVID 19. The ACC is recommending no changes in medical management at this time. Click here for the link to current ACC recommendations (published 3/17).
In light of the current public health crisis due to COVID-19, The Marfan Foundation is providing regular updates for the Marfan, VEDS, Loeys-Dietz, and related condition community. Their Professional Advisory Board has collaborated with us to bring you the best medical information on COVID-19 in relation to our community. Click here to visit The Marfan Foundation page for COVID-19 updates.
Check here for updates on the Alliance and global events related to thoracic aortic disease.
Find the latest research regarding thoracic aortic disease.
Learn about GenTAC related patient registries and their work.